keyword
https://read.qxmd.com/read/37130015/diagnostic-concordance-of-telemedicine-as-compared-with-face-to-face-care-in-primary-health-care-clinics-in-rural-india-randomized-crossover-trial
#61
JOURNAL ARTICLE
Neha Verma, Bimal Buch, Radha Taralekar, Soumyadipta Acharya
BACKGROUND: With the COVID-19 pandemic, there was an increase and scaling up of provider-to-provider telemedicine programs that connect frontline health providers such as nurses and community health workers at primary care clinics with remote doctors at tertiary facilities to facilitate consultations for rural patients. Considering this new trend of increasing use of telemedicine, this study was conducted to generate evidence for patients, health providers, and policymakers to compare if provider-to-provider telemedicine-based care is equivalent to in-person care and is safe and acceptable in terms of diagnostic and treatment standards...
June 23, 2023: JMIR Formative Research
https://read.qxmd.com/read/37065311/the-intersection-between-malaria-treatment-and-chemoprophylaxis-and-their-potential-adverse-dermatologic-manifestations-a-narrative-review
#62
REVIEW
Christopher S Farkouh, Michelle R Anthony, Faiza Amatul, Parsa Abdi, Qaisar Ali Khan
Malaria is a life-threatening parasitic disease caused by various forms of the protozoa Plasmodium and is transmitted by the female Anopheles mosquito. The parasitic infection is endemic in 90 countries, with approximately 500 million cases reported annually and an estimated annual mortality of 1.5-2.7 million individuals. Historically, the use of antimalarial drugs has been promising for the chemoprophylaxis and treatment of malaria, mitigating the annual mortality rate. Notably, these antimalarial drugs have been associated with various adverse effects, including gastrointestinal upset and headaches...
March 2023: Curēus
https://read.qxmd.com/read/37043010/dermatologic-toxicities-of-anti-neoplastic-immunotherapy-in-united-states-hospitalizations
#63
JOURNAL ARTICLE
Shrey Patel, Shiv Patel, Kevin Yang, William C Lau, Vinod E Nambudiri
A major side effect of anti-neoplastic immunotherapy is the onset of dermatologic toxicities following the administration of several different immunotherapy drugs. We sought to assess the incidence and mortality of anti-neoplastic immunotherapy-associated dermatologic toxicities using a nationally representative sample of United States (US) adults. The National Inpatient Sample database was queried for encounters undergoing anti-neoplastic immunotherapy. Multiple logistic regression models were constructed to analyze incidence of dermatologic toxicity and associated mortality as well as calculate adjusted odds ratios (aOR) after controlling for age, race, sex, household income, and cancer type...
April 12, 2023: Archives of Dermatological Research
https://read.qxmd.com/read/37042810/cutaneous-manifestations-induced-by-check-point-inhibitors-in-120-melanoma-patients-the-european-melskintox-study
#64
JOURNAL ARTICLE
J-M L'Orphelin, J Cassecuel, L Kandolf, C A Harwood, P Tookey, M H Junejo, S Hogan, C Lebbé, Z Appalla, T-M Kränke, G Pellacani, D Cerasuolo, B Dujovic, V Del Marmol, A Forschner, C Garbe, V Bataille, J M Ressler, P Sollena, A Dompmartin, K Peris, B Dreno
BACKGROUND: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune-related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD-1i and 50% of CTLA4i-treated patients. Severe cutaneous irAE do not often occur but could be life-threatening and may persist despite treatment discontinuation. METHODS: We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real-world, phase IV, post-marketing study using a follow-up questionnaire...
April 12, 2023: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/37026416/treatment-satisfaction-of-patients-with-psoriasis-with-topical-therapy-in-a-real-world-setting-unmet-need-for-higher-effectiveness
#65
JOURNAL ARTICLE
Nadia Ninosu, Suna Hoelker, Max Kappenstein, Sylvia Buettner, Wiebke K Peitsch, Marthe-Lisa Schaarschmidt
BACKGROUND: Topical medication is the mainstay for treatment of mild psoriasis. However, dissatisfaction with topicals is common and rates of non-adherence are high. Assessing patients' perspectives can help to identify unmet needs. OBJECTIVE: Our aim was to investigate satisfaction of patients with psoriasis with topical therapy and to determine influencing factors. METHODS: Patients were recruited from the Department of Dermatology, University Medical Center Mannheim, Germany...
April 7, 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37004343/nerve-growth-factor-mediates-activation-of-transient-receptor-potential-vanilloid-1-in-neurogenic-pruritus-of-psoriasis
#66
REVIEW
Lin Shang, Siqi Zhao, Huijuan Shi, Xinzhu Xing, Jingya Zhang, Yanling He
Pruritus is a common and painful symptom in psoriasis with profoundly negative impacts on quality of life. The underlying mechanisms of pruritus are complex and multifactorial, and accumulating evidence suggests that pruritus induced by neurogenic inflammation predominates in psoriasis. Nerve growth factor (NGF) -mediated transient receptor potential vanilloid receptor 1(TRPV1) pathway has emerged as a crucial node in the regulation of neurogenic pruritus. TRPV1 appears coupled to most pruritus-specific molecules via the neuro-immune axis...
March 31, 2023: International Immunopharmacology
https://read.qxmd.com/read/37003460/pruritus-in-dermatology-part-2-diseases-and-their-treatment
#67
REVIEW
F J Navarro-Triviño
Pruritus is the main symptom of many dermatologic and systemic diseases. Atopic dermatitis, psoriasis, contact dermatitis, urticaria, lichen simplex chronicus, mycosis fungoides, scars, autoimmune diseases, kidney or liver diseases among others are all associated with itch that may require different approaches to management. Although antihistamines seem to be the first line of therapy, in reality their role is limited to urticaria and drug-induced reactions. In fact, the pathophysiologic mechanisms of each of the conditions covered in this review will differ...
2023: Actas Dermo-sifiliográficas
https://read.qxmd.com/read/36995575/review-of-natural-compounds-for-potential-psoriasis-treatment
#68
REVIEW
Omali Y Elkhawaga, Mohamed M Ellety, Sheref O Mofty, Mohamed S Ghanem, Abdallah O Mohamed
Psoriasis represents an immune-mediated disease with an unclear cause that's marked by inflammation triggered by dysfunction in the immune system, which results in inflammation in various parts of the skin. There could be obvious symptoms, such as elevated plaques; these plaques may appear differently depending on the type of skin. This disease can cause inflammation in the elbows, lower back, scalp, knees, or other regions of the body. It can begin at any age, although it most commonly affects individuals between the ages of 50 and 60...
March 30, 2023: Inflammopharmacology
https://read.qxmd.com/read/36972293/efficacy-and-safety-of-topical-brepocitinib-cream-for-mild-to-moderate-chronic-plaque-psoriasis-a-phase-iib-randomised-double-blind-vehicle-controlled-parallel-group-study
#69
JOURNAL ARTICLE
Megan N Landis, Stacy R Smith, Gabriel Berstein, Gerald Fetterly, Pranab Ghosh, Gang Feng, Vivek Pradhan, Sudeepta Aggarwal, Christopher Banfield, Elena Peeva, Michael S Vincent, Jean S Beebe, Sanela Tarabar
BACKGROUND: Plaque psoriasis (PsO) is an inflammatory skin disease driven, in part, by the activation of Janus kinase (JAK) signalling pathways. OBJECTIVE: To assess the efficacy and safety of multiple doses of topical brepocitinib, a tyrosine kinase 2/JAK1 inhibitor, in participants with mild-to-moderate PsO. METHOD: This phase IIb, multicentre, randomised, double-blind study was conducted in two stages. In stage one, participants received one of eight treatments for 12 weeks: brepocitinib 0·1% once daily (QD), 0·3% QD or twice daily (BID), 1·0% QD or BID, 3·0% QD, or vehicle QD or BID...
March 27, 2023: British Journal of Dermatology
https://read.qxmd.com/read/36967545/neuroimmune-mediators-of-pruritus-in-hispanic-scalp-psoriatic-itch
#70
JOURNAL ARTICLE
Leigh A Nattkemper, Zoe M Lipman, Giuseppe Ingrasci, Claudia Maldonado, Juan Carlos Garces, Enrique Loayza, Gil Yosipovitch
Scalp psoriatic itch is a common, bothersome, yet understudied, condition with numerous associated treatment challenges. The aim of this study was to enhance our understanding of the pathophysiology of scalp psoriatic itch. Immunohistochemical analysis of known neuroimmune mediators of pruritus was conducted using scalp biopsies from 27 Hispanic psoriatic patients. Patients were categorized into mild/moderate or severe itch groups according to their itch intensity rating of scalp itch. Protease activated receptor (PAR2), substance P, transient receptor potential (TRP)V3, TRPM8 and interleukin-23 expression all correlated  significantly with itch intensity...
March 23, 2023: Acta Dermato-venereologica
https://read.qxmd.com/read/36938293/a-reversible-cause-of-cutaneous-rash-in-a-patient-with-alcohol-consumption
#71
Asim Haider, Hitesh Gurjar, Haider Ghazanfar, Himani Singh, Ayesha Siddiqa
The most common cutaneous manifestations of alcoholism include urticarial reaction, flushing, porphyria cutanea tarda, psoriasis, rosacea, seborrheic dermatitis, and pruritus. Here, we present a case of a young male with a history of alcohol abuse who presented with non-blanching, petechial, and perifollicular macular rash secondary to vitamin C deficiency in view of poor oral intake. The rash improved significantly with vitamin C supplementation. Although rare in developed countries, clinicians should keep vitamin C deficiency as a differential diagnosis for skin rash in alcohol consumers...
February 2023: Curēus
https://read.qxmd.com/read/36877880/patient-preference-for-calcipotriene-and-betamethasone-dipropionate-cream-versus-foam-for-the-topical-treatment-of-psoriasis-a-pilot-study
#72
JOURNAL ARTICLE
Charles Kircik, Leon Kircik
BACKGROUND: The well-established sequential use of topical calcipotriene and topical betamethasone dipropionate in combination has been shown to provide greater benefit than either monotherapy. A newer topical fixed combination formulation of calcipotriene 0.005% and betamethasone dipropionate 0.064% in a cream base (Cal/BD cream) is effective with high patient ratings for convenience and tolerability. The current study compares patient satisfaction between Cal/BD foam and Cal/BD cream formulations...
March 1, 2023: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/36876220/endogenous-derivatives-of-linoleic-acid-and-their-stable-analogs-are-potential-pain-mediators
#73
JOURNAL ARTICLE
Joshua J Wheeler, Anthony F Domenichiello, Jennifer R Jensen, Gregory S Keyes, Kristen M Maiden, John M Davis, Christopher E Ramsden, Santosh K Mishra
Psoriasis is characterized by intense pruritus, with a subset of individuals with psoriasis experiencing thermal hypersensitivity. However, the pathophysiology of thermal hypersensitivity in psoriasis and other skin conditions remains enigmatic. Linoleic acid is an omega-6 fatty acid that is concentrated in the skin, and oxidation of linoleic acid into metabolites with multiple hydroxyl and epoxide functional groups has been shown to play a role in skin barrier function. Previously, we identified several linoleic acid‒derived mediators that were more concentrated in psoriatic lesions, but the role of these lipids in psoriasis remains unknown...
March 2023: JID innovations
https://read.qxmd.com/read/36874763/circumscribed-palmar-hypokeratosis-with-superimposed-actinic-keratosis
#74
Erica Aukerman, Megana Rao, Azadeh Samiei, Maria C Bell, Sahand Rahnama-Moghadam
A man in his late 70s with a history of psoriasis and non-melanoma skin cancer presented with a progressive rash on his right thenar eminence. He first noticed it about one year ago. He denied any pruritus in the affected region but did note some overlying skin breakdown. He had used topical betamethasone and calcipotriene cream in the past with minimal improvement. Physical examination revealed a pink atrophic plaque with linear hyperkeratotic borders and central fissuring on the right thenar eminence extending into the first webspace...
January 2023: Curēus
https://read.qxmd.com/read/36800804/a-novel-moisture-for-xerosis-in-psoriatic-patients-a-single-center-study
#75
JOURNAL ARTICLE
Martina Burlando, Riccardo Castelli, Ilaria Salvi, Emanuele Cozzani, Aurora Parodi
BACKGROUND: Xerosis is an extremely common condition, especially in the elderly population. It is the most common cause of pruritus in the older adult. Since xerosis is generally caused by a lack of epidermal lipids, the use of leave-on skin care products is the mainstay treatment. The aim of this open prospective analytical observational study was to investigate the clinical and self-reported hydrating efficacy of a moisturizer formulation containing a synergy between amino-inositol and urea (INOSIT-U 20) in patients with psoriasis and xerosis...
February 21, 2023: Italian journal of dermatology and venereology
https://read.qxmd.com/read/36790724/a-review-on-the-safety-of-using-jak-inhibitors-in-dermatology-clinical-and-laboratory-monitoring
#76
REVIEW
Christeen Samuel, Hannah Cornman, Anusha Kambala, Shawn G Kwatra
Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions. The US Food and Drug Administration (FDA) recently placed a black box warning on this class of medications due to safety concerns based on data from studies investigating tofacitinib in patients with rheumatoid arthritis. Here we provide an overview of the timeline of FDA approval of JAK inhibitors in dermatology. We also discuss the available safety profiles of approved oral JAK1 inhibitors, namely abrocitinib and upadacitinib, oral baricitinib, a JAK1/2 inhibitor, deucravacitinib, a Tyk2 inhibitor, and the topical JAK1/2 inhibitor ruxolitinib in dermatology patients...
March 2023: Dermatology and Therapy
https://read.qxmd.com/read/36789757/itch-and-janus-kinase-inhibitors
#77
REVIEW
Yujin Han, Yu Ri Woo, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a signalling mechanism that regulates gene expression through various cytokines. Janus kinase inhibitors, which have been tested and used for several autoimmune diseases, have also been shown to be effective for itch through clinical trials and case reports...
February 15, 2023: Acta Dermato-venereologica
https://read.qxmd.com/read/36786739/psoriatic-insomnia-a-subjective-and-objective-sleep-evaluation
#78
JOURNAL ARTICLE
Katerina Vlami, Kleoniki Pantelidi, Maria Dalamaga, Fani Karagianni, Konstantinos Theodoropoulos, Spyridon Papiris, Evangelia Papadavid
Psoriasis may affect patients' sleep. In order to examine this relationship, this study evaluated non-anxious and non-depressive patients with moderate to severe psoriasis before and after 6 months of systemic treatment. A prospective case-control study with 46 consecutive patients (mean age 51.1 ± 12.8 years, 18 women) and 24 age-, sex- and body mass index-matched controls (mean age 46.5 ± 15.4 years, 12 women) was conducted to assess sleep using both sleep questionnaires and actigraphy...
February 14, 2023: Acta Dermato-venereologica
https://read.qxmd.com/read/36769042/rare-phytocannabinoids-exert-anti-inflammatory-effects-on-human-keratinocytes-via-the-endocannabinoid-system-and-mapk-signaling-pathway
#79
JOURNAL ARTICLE
Daniel Tortolani, Camilla Di Meo, Sara Standoli, Francesca Ciaramellano, Salam Kadhim, Eric Hsu, Cinzia Rapino, Mauro Maccarrone
Increasing evidence supports the therapeutic potential of rare cannabis-derived phytocannabinoids (pCBs) in skin disorders such as atopic dermatitis, psoriasis, pruritus, and acne. However, the molecular mechanisms of the biological action of these pCBs remain poorly investigated. In this study, an experimental model of inflamed human keratinocytes (HaCaT cells) was set up by using lipopolysaccharide (LPS) in order to investigate the anti-inflammatory effects of the rare pCBs cannabigerol (CBG), cannabichromene (CBC), Δ9 -tetrahydrocannabivarin (THCV) and cannabigerolic acid (CBGA)...
February 1, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36768135/increased-serum-levels-of-tumor-necrosis-factor-like-ligand-1a-in-atopic-dermatitis
#80
JOURNAL ARTICLE
Teruyoshi Hisamoto, Hiraku Suga, Asako Yoshizaki-Ogawa, Shinichi Sato, Ayumi Yoshizaki
Atopic dermatitis (AD) is a common chronic skin disease with pruritus, affecting 5-20% of the population in developed countries. Though its cause varies from genetic polymorphisms to the environmental factors, the T-helper (Th) 2 inflammation is one of the main characteristic pathoses. TNF superfamily ligand A (TL1A) is a recently discovered cytokine, which is released by various immune cells and reported to have an ability to stimulate Th1, Th2, and Th17 responses. Its association was investigated in chronic inflammatory disease, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis...
January 17, 2023: International Journal of Molecular Sciences
keyword
keyword
14346
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.